Analysis Article • 13h
Have your own idea? Try our Stock Screener
Hong Kong (HSI) Biotech Industry Analysis
UpdatedAug 20, 2026
DataAggregated Company Financials
Companies67
- 7D-4.5%
- 3M-6.6%
- 1Y-24.5%
- YTD-11.6%
Over the last 7 days, the Biotech industry has dropped 4.5%, driven by a pullback from Akeso of 13%. However, the industry is down 25% over the past year. Earnings are forecast to grow by 32% annually.
Industry Valuation and Performance
Has the Hong Kong Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 20 Aug 2026 | HK$931.8b | HK$96.1b | -HK$2,990,034,400.29 | 25.1x | -311.6x | 9.7x |
| Sat, 18 Jul 2026 | HK$879.5b | HK$94.5b | -HK$4,117,901,026.07 | 19.6x | -213.6x | 9.3x |
| Mon, 15 Jun 2026 | HK$827.7b | HK$94.8b | -HK$4,484,429,393.98 | 17.9x | -184.6x | 8.7x |
| Wed, 13 May 2026 | HK$1.0t | HK$94.3b | -HK$3,918,869,452.62 | 22.7x | -257x | 10.7x |
| Fri, 10 Apr 2026 | HK$1.1t | HK$92.9b | -HK$3,765,777,446.57 | 27.7x | -289.8x | 11.7x |
| Sun, 08 Mar 2026 | HK$943.3b | HK$72.6b | -HK$11,934,310,073.47 | 49.6x | -79x | 13x |
| Tue, 03 Feb 2026 | HK$923.1b | HK$70.4b | -HK$14,001,050,699.50 | 32.6x | -65.9x | 13.1x |
| Thu, 01 Jan 2026 | HK$913.9b | HK$69.9b | -HK$13,808,618,829.21 | 36.7x | -66.2x | 13.1x |
| Sat, 29 Nov 2025 | HK$1.0t | HK$69.2b | -HK$12,917,634,916.55 | 41.4x | -81.1x | 15.1x |
| Mon, 27 Oct 2025 | HK$989.0b | HK$68.2b | -HK$13,130,210,606.67 | 45.3x | -75.3x | 14.5x |
| Wed, 24 Sep 2025 | HK$1.1t | HK$68.5b | -HK$13,353,323,029.41 | 48.4x | -83.8x | 16.4x |
| Fri, 22 Aug 2025 | HK$1.1t | HK$63.4b | -HK$12,664,785,158.75 | 50.5x | -85.7x | 17.1x |
| Sun, 20 Jul 2025 | HK$911.3b | HK$63.7b | -HK$12,190,686,816.03 | 38.2x | -74.8x | 14.3x |
| Tue, 17 Jun 2025 | HK$743.9b | HK$62.2b | -HK$11,783,657,962.79 | 35.6x | -63.1x | 12x |
| Thu, 15 May 2025 | HK$553.0b | HK$61.6b | -HK$11,837,331,364.97 | 29.2x | -46.7x | 9x |
| Sat, 12 Apr 2025 | HK$501.4b | HK$58.1b | -HK$10,821,518,059.10 | 26.3x | -46.3x | 8.6x |
| Mon, 10 Mar 2025 | HK$461.2b | HK$52.5b | -HK$16,893,132,103.38 | 22.7x | -27.3x | 8.8x |
| Wed, 05 Feb 2025 | HK$358.8b | HK$52.3b | -HK$17,392,018,984.26 | 12.6x | -20.6x | 6.9x |
| Fri, 03 Jan 2025 | HK$367.2b | HK$51.9b | -HK$17,241,784,830.06 | 10.8x | -21.3x | 7.1x |
| Sun, 01 Dec 2024 | HK$399.6b | HK$52.3b | -HK$17,390,148,785.72 | 10.7x | -23x | 7.6x |
| Tue, 29 Oct 2024 | HK$392.5b | HK$52.3b | -HK$17,891,036,991.36 | 11.4x | -21.9x | 7.5x |
| Thu, 26 Sep 2024 | HK$355.1b | HK$53.0b | -HK$18,425,985,001.97 | 11x | -19.3x | 6.7x |
| Sat, 24 Aug 2024 | HK$332.2b | HK$53.4b | -HK$18,895,611,066.02 | 11x | -17.6x | 6.2x |
| Mon, 22 Jul 2024 | HK$324.3b | HK$49.6b | -HK$19,438,335,694.28 | 12.6x | -16.7x | 6.5x |
| Wed, 19 Jun 2024 | HK$338.1b | HK$49.7b | -HK$19,469,839,436.05 | 10.5x | -17.4x | 6.8x |
| Fri, 17 May 2024 | HK$371.5b | HK$49.9b | -HK$19,423,587,854.26 | 12.1x | -19.1x | 7.4x |
| Sun, 14 Apr 2024 | HK$341.5b | HK$49.6b | -HK$19,926,257,322.48 | 11x | -17.1x | 6.9x |
| Tue, 12 Mar 2024 | HK$345.7b | HK$47.3b | -HK$20,415,595,754.97 | 16.5x | -16.9x | 7.3x |
| Thu, 08 Feb 2024 | HK$321.9b | HK$47.2b | -HK$20,396,378,333.69 | 15.5x | -15.8x | 6.8x |
| Sat, 06 Jan 2024 | HK$376.6b | HK$47.1b | -HK$20,327,490,552.00 | 16.9x | -18.5x | 8x |
| Mon, 04 Dec 2023 | HK$427.8b | HK$47.0b | -HK$20,310,389,111.00 | 18.9x | -21.1x | 9.1x |
| Wed, 01 Nov 2023 | HK$413.5b | HK$45.0b | -HK$18,757,275,840.00 | 13.2x | -22x | 9.2x |
| Fri, 29 Sep 2023 | HK$408.6b | HK$44.9b | -HK$19,123,315,931.00 | 14.3x | -21.4x | 9.1x |
| Sun, 27 Aug 2023 | HK$373.5b | HK$39.2b | -HK$20,093,496,287.00 | 15.7x | -18.6x | 9.5x |
Price to Earnings Ratio
-18.6x
Current Industry PE
- Investors are relatively neutral on the Hong Kong Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 9.9x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have improved over the last three years.
- Revenues for these companies have grown 35% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Trends
Which industries have driven the changes within the Hong Kong Healthcare industry?
| HK Market | 0.41% | |
| Healthcare | -2.56% | |
| Biotech | -4.55% | |
| Biotech | -4.55% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 1801 Innovent Biologics | HK$101.20 | 6.4% +HK$10.5b | 1.9% | PE185.7x | |
| 7666 Metis TechBio | HK$15.00 | 13.7% +HK$2.1b | n/a | PS144.9x | |
| 1952 Everest Medicines | HK$33.66 | 18.4% +HK$1.8b | -51.4% | PS4.2x | |
| 6990 Sichuan Kelun-Biotech Biopharmaceutical | HK$533.00 | 1.4% +HK$1.8b | 17.5% | PE722.6x | |
| 6185 CanSino Biologics | HK$32.06 | 26.0% +HK$1.6b | -34.3% | PS6.1x |
